Skip to main content

Vermillion's Aspira Labs Wins Coverage from BCBS of Michigan for OVA1

NEW YORK (360Dx) – Vermillion said yesterday that Blue Cross Blue Shield (BCBS) of Michigan has agreed to cover its OVA1 ovarian cancer test.

BCBS of Michigan covers more than 6 million people in Michigan and the larger Great Lakes region.

Valerie Palmieri, president and CEO of Vermillion, said in a statement that the company continues to execute on its managed care strategy and that Michigan and the surrounding region are an area of focus for its commercialization efforts.

Vermillion signed an agreement in July with Michigan healthcare insurance company Priority Health Managed Benefits.

OVA1 is a proteomic test intended for use in patients with an adnexal mass to determine prior to surgery whether the mass is likely malignant or benign and help physicians decide if a patient should be passed on to a gynecologic oncologist for the procedure.